Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients

References

• Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9(4):822–830. doi:10.1002/1097-0142(195607/08)9:4<822:AID-CNCR2820090430>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015;56(5):1252–1260. doi:10.3109/10428194.2014.953145
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353–1364. doi:10.1182/blood.2019000931
   PubMed Web of Science ®Google Scholar
• Yu L, Tu M, Cortes J, et al. Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease. Blood. 2017;129(12):1658–1668. doi:10.1182/blood-2016-11-748855
   PubMed Web of Science ®Google Scholar
• van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–2124. doi:10.1182/blood-2018-07-862334
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123(19):2924–2933. doi:10.1182/blood-2013-12-545087
   PubMed Web of Science ®Google Scholar
• Abramson JS. Diagnosis and management of Castleman disease. J Natl Compr Canc Netw. 2019;17:1417–1419. doi:10.6004/jnccn.2019.5037
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646–1657. doi:10.1182/blood-2016-10-746933
   PubMed Web of Science ®Google Scholar
• Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670–683.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Sakai T, Kawabata H, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94(9):975–983. doi:10.1002/ajh.25554
   PubMed Web of Science ®Google Scholar
• Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification, and treatment strategy for a novel disorder; TAFRO syndrome. Rinsho Ketsueki. 2016;57(10):2029–2037. doi:10.11406/rinketsu.57.2029
   PubMedGoogle Scholar
• Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53(1):57–61. doi:10.3960/jslrt.53.57
   PubMedGoogle Scholar
• Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91(2):220–226. doi:10.1002/ajh.24242
   PubMed Web of Science ®Google Scholar
• Masaki Y, Kawabata H, Takai K, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111(1):155–158. doi:10.1007/s12185-019-02780-1
   PubMed Web of Science ®Google Scholar
• Hillman SL, An MW, O’Connell MJ, et al. Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. J Clin Oncol. 2009;27(19):3205–3210. doi:10.1200/JCO.2008.18.3269
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022;6(2):359–367. doi:10.1182/bloodadvances.2021004441
   PubMed Web of Science ®Google Scholar
• Tang JQ, Chen HK, Wang X, et al. Retrospective analysis of 45 cases of localized retroperitoneal Castleman disease from a single center. Hepatobiliary Surg Nutr. 2020;9(3):304–311. doi:10.21037/hbsn.2019.05.05
   PubMed Web of Science ®Google Scholar
• Zhang X, Rao H, Xu X, et al. Clinical characteristics and outcomes of Castleman disease: a multicenter study of 185 Chinese patients. Cancer Sci. 2018;109(1):199–206. doi:10.1111/cas.13439
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180(2):206–216. doi:10.1111/bjh.15019
   PubMed Web of Science ®Google Scholar
• Dong Y, Wang M, Nong L, et al. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol. 2015;169(6):834–842. doi:10.1111/bjh.13378
   PubMed Web of Science ®Google Scholar
• Borocco C, Ballot-Schmit C, Ackermann O, et al. The French paediatric cohort of Castleman disease: a retrospective report of 23 patients. Orphanet J Rare Dis. 2020;15(1):95. doi:10.1186/s13023-020-1345-5
   PubMed Web of Science ®Google Scholar
• van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020;4(23):6039–6050. doi:10.1182/bloodadvances.2020003334
   PubMed Web of Science ®Google Scholar
• Wang W, Dong D, Wen J, Li H. A 10-year observational single-center study of retroperitoneal unicentric Castleman disease. Medicine. 2021;100(10):e25088. doi:10.1097/MD.0000000000025088
   PubMed Web of Science ®Google Scholar
• Jiang Y, Hou G, Zhu Z, Huo L, Cheng W, Li F. The value of multiparameter (18) F-FDG PET/CT imaging in differentiating retroperitoneal paragangliomas from unicentric Castleman disease. Sci Rep. 2020;10(1):12887. doi:10.1038/s41598-020-69854-7
   PubMed Web of Science ®Google Scholar
• Boutboul D, Fadlallah J, Chawki S, et al. Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019;186(2):269–273. doi:10.1111/bjh.15921
   PubMed Web of Science ®Google Scholar
• Neuhof D, Debus J. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol. 2006;45(8):1126–1131. doi:10.1080/02841860600812701
   PubMed Web of Science ®Google Scholar
• Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92(3):670–676. doi:10.1002/1097-0142(20010801)92:3<670:AID-CNCR1369>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Zhang Y, Suo SS, Yang HJ, et al. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study. J Cancer Res Clin Oncol. 2020;146(2):357–365. doi:10.1007/s00432-019-03120-w
   PubMed Web of Science ®Google Scholar
• Han EJ, JH O, Jung SE, et al. FDG PET/CT findings of Castleman disease assessed by histologic subtypes and compared with laboratory findings. Diagnostics. 2020;10:12.
   Web of Science ®Google Scholar
• Tonelli M, Sacks F, Arnold M, et al. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation. 2008;117(2):163–168. doi:10.1161/CIRCULATIONAHA.107.727545
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–1965. doi:10.1056/NEJM200106283442601
   PubMed Web of Science ®Google Scholar
• Baba Y, Saito B, Shimada S, et al. Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. Leuk Res. 2018;67:56–59. doi:10.1016/j.leukres.2018.02.004
   PubMed Web of Science ®Google Scholar
• Winchester LM, Powell J, Lovestone S, Nevado-Holgado AJ. Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease. Genome Med. 2018;10(1):51. doi:10.1186/s13073-018-0556-z
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood. 2018;132(22):2323–2330. doi:10.1182/blood-2018-05-848671
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood. 2019;133(16):1720–1728. doi:10.1182/blood-2018-11-884577
   PubMed Web of Science ®Google Scholar
• van Rhee F, Casper C, Voorhees PM, et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020;7(3):e209–e217. doi:10.1016/S2352-3026(19)30257-1
   PubMed Web of Science ®Google Scholar
• Deisseroth A, Ko CW, Nie L, et al. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res. 2015;21(5):950–954. doi:10.1158/1078-0432.CCR-14-1678
   PubMed Web of Science ®Google Scholar
• van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–974. doi:10.1016/S1470-2045(14)70319-5
   PubMed Web of Science ®Google Scholar
• Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman’s disease. J Clin Oncol. 2011;29(18):2481–2486. doi:10.1200/JCO.2010.34.1909
   PubMed Web of Science ®Google Scholar
• Flahault A, Vignon M, Rabant M, et al. Case report and literature review: glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric Castleman disease. Medicine. 2016;95(41):e5047. doi:10.1097/MD.0000000000005047
   PubMed Web of Science ®Google Scholar
• Miura A, Sato I, Suzuki C. Fatal diarrhea in a patient with Castleman’s disease associated with intestinal amyloidosis. Intern Med. 1995;34(11):1106–1109. doi:10.2169/internalmedicine.34.1106
   PubMed Web of Science ®Google Scholar
• Yavasoglu I, Kadikoylu G, Meteoglu I, Bolaman Z. Hyaline-vascular type of Castleman's disease associated with Crohn’s disease. Int J Colorectal Dis. 2009;24(1):123–124. doi:10.1007/s00384-008-0545-6
   PubMed Web of Science ®Google Scholar